faxitron dxa scan Search Results


ex vivo dual energy x ray absorptiometry dexa  (Faxitron Bioptics)
86
Faxitron Bioptics ex vivo dual energy x ray absorptiometry dexa
Small animal [ 89 Zr]-DFO-daratumumab confirms absence of hCD38 expression in vivo in MM.1S WT cells. (A) Cell binding of [ 89 Zr]-DFO-daratumumab to a murine MM cell line with hCD38 expression knocked in (5TGM1-hCD38-KI cells). (B) Representative 30-minute static PET/CT scans of MM.1S WT and MM.1S CD38 KO tumor bearing mice at 3 and 6 days after injection of [ 89 Zr]-DFO-daratumumab. Areas of high tracer uptake in the bones are indicated by white arrows. (C) Comparative quantification of SUV max between WT and CD38 KO tumor bearing mice at 6 days post-injection of [ 89 Zr]-DFO-daratumumab (2-way ANOVA; ns P > .05; ∗∗∗∗ P < .001). (D) Comparative quantification of the tissue density (Hounsfield units, HU) from in vivo CT across corresponding bone ROIs in MM.1S WT and MM.1S CD38 KO tumor bearing mice (2-way ANOVA; ns P > .05; ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .005; ∗∗∗∗ P < .001). (E) Comparative quantification of the BMD (milligram per square centimeter) of each bone ROI using <t>DEXA</t> imaging between MM.1S WT and MM.1S CD38 KO tumor bearing mice (2-way ANOVA; ns P > .05; ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .001). (F) <t>Planar</t> <t>X-ray</t> images of the femur and tibia from mice implanted with WT and CD38 KO MM cells reveal potential osteolytic lesions of the cortical and trabecular bone, marked by white arrows, indicating areas of bone degradation.
Ex Vivo Dual Energy X Ray Absorptiometry Dexa, supplied by Faxitron Bioptics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/faxitron+dxa+scan/absorptiometry+dual+energy+ray+x/pmc12828765-45-0-10
Average 86 stars, based on 1 article reviews
ex vivo dual energy x ray absorptiometry dexa - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
dexa  (Faxitron Bioptics)
86
Faxitron Bioptics dexa
Small animal [ 89 Zr]-DFO-daratumumab confirms absence of hCD38 expression in vivo in MM.1S WT cells. (A) Cell binding of [ 89 Zr]-DFO-daratumumab to a murine MM cell line with hCD38 expression knocked in (5TGM1-hCD38-KI cells). (B) Representative 30-minute static PET/CT scans of MM.1S WT and MM.1S CD38 KO tumor bearing mice at 3 and 6 days after injection of [ 89 Zr]-DFO-daratumumab. Areas of high tracer uptake in the bones are indicated by white arrows. (C) Comparative quantification of SUV max between WT and CD38 KO tumor bearing mice at 6 days post-injection of [ 89 Zr]-DFO-daratumumab (2-way ANOVA; ns P > .05; ∗∗∗∗ P < .001). (D) Comparative quantification of the tissue density (Hounsfield units, HU) from in vivo CT across corresponding bone ROIs in MM.1S WT and MM.1S CD38 KO tumor bearing mice (2-way ANOVA; ns P > .05; ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .005; ∗∗∗∗ P < .001). (E) Comparative quantification of the BMD (milligram per square centimeter) of each bone ROI using <t>DEXA</t> imaging between MM.1S WT and MM.1S CD38 KO tumor bearing mice (2-way ANOVA; ns P > .05; ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .001). (F) <t>Planar</t> <t>X-ray</t> images of the femur and tibia from mice implanted with WT and CD38 KO MM cells reveal potential osteolytic lesions of the cortical and trabecular bone, marked by white arrows, indicating areas of bone degradation.
Dexa, supplied by Faxitron Bioptics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/faxitron+dxa+scan/dexa/pm41723149-247-19-27
Average 86 stars, based on 1 article reviews
dexa - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
faxitron dxa scan  (Faxitron Bioptics)
86
Faxitron Bioptics faxitron dxa scan
Small animal [ 89 Zr]-DFO-daratumumab confirms absence of hCD38 expression in vivo in MM.1S WT cells. (A) Cell binding of [ 89 Zr]-DFO-daratumumab to a murine MM cell line with hCD38 expression knocked in (5TGM1-hCD38-KI cells). (B) Representative 30-minute static PET/CT scans of MM.1S WT and MM.1S CD38 KO tumor bearing mice at 3 and 6 days after injection of [ 89 Zr]-DFO-daratumumab. Areas of high tracer uptake in the bones are indicated by white arrows. (C) Comparative quantification of SUV max between WT and CD38 KO tumor bearing mice at 6 days post-injection of [ 89 Zr]-DFO-daratumumab (2-way ANOVA; ns P > .05; ∗∗∗∗ P < .001). (D) Comparative quantification of the tissue density (Hounsfield units, HU) from in vivo CT across corresponding bone ROIs in MM.1S WT and MM.1S CD38 KO tumor bearing mice (2-way ANOVA; ns P > .05; ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .005; ∗∗∗∗ P < .001). (E) Comparative quantification of the BMD (milligram per square centimeter) of each bone ROI using <t>DEXA</t> imaging between MM.1S WT and MM.1S CD38 KO tumor bearing mice (2-way ANOVA; ns P > .05; ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .001). (F) <t>Planar</t> <t>X-ray</t> images of the femur and tibia from mice implanted with WT and CD38 KO MM cells reveal potential osteolytic lesions of the cortical and trabecular bone, marked by white arrows, indicating areas of bone degradation.
Faxitron Dxa Scan, supplied by Faxitron Bioptics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/faxitron+dxa+scan/dxa+faxitron+ultrafocus/us12440522-1304-21-21
Average 86 stars, based on 1 article reviews
faxitron dxa scan - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


Small animal [ 89 Zr]-DFO-daratumumab confirms absence of hCD38 expression in vivo in MM.1S WT cells. (A) Cell binding of [ 89 Zr]-DFO-daratumumab to a murine MM cell line with hCD38 expression knocked in (5TGM1-hCD38-KI cells). (B) Representative 30-minute static PET/CT scans of MM.1S WT and MM.1S CD38 KO tumor bearing mice at 3 and 6 days after injection of [ 89 Zr]-DFO-daratumumab. Areas of high tracer uptake in the bones are indicated by white arrows. (C) Comparative quantification of SUV max between WT and CD38 KO tumor bearing mice at 6 days post-injection of [ 89 Zr]-DFO-daratumumab (2-way ANOVA; ns P > .05; ∗∗∗∗ P < .001). (D) Comparative quantification of the tissue density (Hounsfield units, HU) from in vivo CT across corresponding bone ROIs in MM.1S WT and MM.1S CD38 KO tumor bearing mice (2-way ANOVA; ns P > .05; ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .005; ∗∗∗∗ P < .001). (E) Comparative quantification of the BMD (milligram per square centimeter) of each bone ROI using DEXA imaging between MM.1S WT and MM.1S CD38 KO tumor bearing mice (2-way ANOVA; ns P > .05; ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .001). (F) Planar X-ray images of the femur and tibia from mice implanted with WT and CD38 KO MM cells reveal potential osteolytic lesions of the cortical and trabecular bone, marked by white arrows, indicating areas of bone degradation.

Journal: Blood Advances

Article Title: Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model

doi: 10.1182/bloodadvances.2025017296

Figure Lengend Snippet: Small animal [ 89 Zr]-DFO-daratumumab confirms absence of hCD38 expression in vivo in MM.1S WT cells. (A) Cell binding of [ 89 Zr]-DFO-daratumumab to a murine MM cell line with hCD38 expression knocked in (5TGM1-hCD38-KI cells). (B) Representative 30-minute static PET/CT scans of MM.1S WT and MM.1S CD38 KO tumor bearing mice at 3 and 6 days after injection of [ 89 Zr]-DFO-daratumumab. Areas of high tracer uptake in the bones are indicated by white arrows. (C) Comparative quantification of SUV max between WT and CD38 KO tumor bearing mice at 6 days post-injection of [ 89 Zr]-DFO-daratumumab (2-way ANOVA; ns P > .05; ∗∗∗∗ P < .001). (D) Comparative quantification of the tissue density (Hounsfield units, HU) from in vivo CT across corresponding bone ROIs in MM.1S WT and MM.1S CD38 KO tumor bearing mice (2-way ANOVA; ns P > .05; ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .005; ∗∗∗∗ P < .001). (E) Comparative quantification of the BMD (milligram per square centimeter) of each bone ROI using DEXA imaging between MM.1S WT and MM.1S CD38 KO tumor bearing mice (2-way ANOVA; ns P > .05; ∗ P < .05; ∗∗ P < .01; ∗∗∗∗ P < .001). (F) Planar X-ray images of the femur and tibia from mice implanted with WT and CD38 KO MM cells reveal potential osteolytic lesions of the cortical and trabecular bone, marked by white arrows, indicating areas of bone degradation.

Article Snippet: Ex vivo dual-energy X-ray absorptiometry (DEXA) was performed using a Faxitron UltraFocus100 system.

Techniques: Expressing, In Vivo, Binding Assay, Positron Emission Tomography-Computed Tomography, Injection, Imaging